7Stinchcombe TE,Socinski MA.Considerations for second-line therapy of non-small cell lung cancer.Oncologist,2008,13(suppl 1):28-36.
8Calvert H.An overview of folate metabolism:Features relevant to the action and toxicities of antifolate anticancer agents.Semin Oncol,1999,26(2 Suppl 6):3.
9Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22 (9):1589-1597.
10Russo F,Bearz A,Pampaloni G.Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.BMC Cancer,2008,8:216.
1Jiang J T, Xu N, Wu C P, et al. Treatment of advanced gas- triccancer by chemotherapy combined with autologous oytokine -induced killer cells [ J ]. Antieancer Res, 2006, 26 (3B) : 2237.
2Tomas L, Sandra W, Cbrisian S, et al. A phase Ⅱ trial of auto -logouscytoking-induced killer cells for the treatment of re- lapsed Hodgkin disease and non-hodgkin lymphoma[ J ]. Biology of Blood and Marrow Transplantation Ⅱ, 2005, 11 : 181.
